Literature DB >> 2570432

Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.

J Lappalainen1, J Hietala, E Syvälahti.   

Abstract

The development of tolerance to the cataleptic effect of the selective D-1 antagonist SCH 23390 (0.5 mg/kg/day SC or 0.1 mg/kg/day SC) and haloperidol (1 mg/kg/day SC) during repeated administration was investigated. Catalepsy in rats was measured using the horizontal bar method. SCH 23390 induced a dose-related cataleptic effect of short duration, whereas the cataleptic effect of haloperidol appeared more slowly and lasted longer. Marked tolerance to the cataleptic effect of haloperidol developed already 6 days from the beginning of the treatment. The cataleptic effect of the higher dose regimen of SCH 23390 was also significantly reduced after 6 days' treatment. However, unlike haloperidol, this subacute tolerance was gradually reversed and was no longer significant after 12 and 18 days. The cataleptic response to the lower dose of SCH 23390 (0.1 mg/kg/day) was not significantly altered during the treatment and no initial catalepsy tolerance was observed with this dose regimen. These results suggest that different mechanisms are involved in the expression of cataleptic behaviour during chronic treatment with SCH 23390 and classical antipsychotics, such as haloperidol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570432     DOI: 10.1007/BF00441944

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.

Authors:  C J de Graaf; J Korf
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  D1- and D2-receptor antagonists induce catalepsy via different efferent striatal pathways [corrected].

Authors:  S O Ogren; K Fuxe
Journal:  Neurosci Lett       Date:  1988-03-10       Impact factor: 3.046

3.  The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors.

Authors:  S Bischoff; M Heinrich; J M Sonntag; J Krauss
Journal:  Eur J Pharmacol       Date:  1986-10-07       Impact factor: 4.432

4.  5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain.

Authors:  P E Hicks; H Schoemaker; S Z Langer
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

5.  Quantification of R-(+)-7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-methyl-3- benzazepine in brain and blood by use of reversed-phase high-performance liquid chromatography with electrochemical detection.

Authors:  C D Kilts; K L Dew; T D Ely; R B Mailman
Journal:  J Chromatogr       Date:  1985-08-09

6.  Tolerance to behavioral effects of haloperidol.

Authors:  A Campbell; R J Baldessarini
Journal:  Life Sci       Date:  1981-09-28       Impact factor: 5.037

7.  Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.

Authors:  E J Hess; L J Albers; H Le; I Creese
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

8.  Catalepsy induced by SCH 23390 in rats.

Authors:  M Morelli; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1985-11-05       Impact factor: 4.432

9.  Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics.

Authors:  A V Christensen; J Arnt; J Hyttel; J J Larsen; O Svendsen
Journal:  Life Sci       Date:  1984-04-16       Impact factor: 5.037

10.  Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist.

Authors:  E Meller; S Kuga; A J Friedhoff; M Goldstein
Journal:  Life Sci       Date:  1985-05-13       Impact factor: 5.037

View more
  2 in total

1.  The Arousal-motor Hypothesis of Dopamine Function: Evidence that Dopamine Facilitates Reward Seeking in Part by Maintaining Arousal.

Authors:  Marcin Kaźmierczak; Saleem M Nicola
Journal:  Neuroscience       Date:  2022-07-16       Impact factor: 3.708

2.  Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood.

Authors:  J Hietala; T Seppäla; J Lappalainen; E Syvälahti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.